Advanced Enzyme FY26 results: revenue ₹745.76 crore

Board clears audited FY26 numbers

Advanced Enzyme Technologies said its Board of Directors approved the audited standalone and consolidated financial results for the year ended March 31, 2026, along with the audited fourth-quarter results. The board meeting was held on May 09, 2026. The company also outlined a set of corporate actions, including a final dividend recommendation, director-related approvals, auditor reappointment, and an ESOP allotment. The disclosures were made as part of regulatory communication to the stock exchanges.

Consolidated FY26 performance led by higher revenue

On a consolidated basis, revenue from operations increased to ₹745.76 crore in FY26 from ₹636.91 crore in FY25. Consolidated net profit rose to ₹173.61 crore from ₹133.97 crore a year earlier. Total comprehensive income for FY26 was ₹268.42 crore compared with ₹152.80 crore in FY25. The company also disclosed that FY26 profit margin was 23.26% based on its consolidated figures.

Q4 FY26 snapshot and earnings per share

For Q4 FY26 (audited), consolidated revenue from operations was reported at ₹203.37 crore versus ₹167.18 crore in Q4 FY25. Total comprehensive income for the quarter stood at ₹93.19 crore compared with ₹27.39 crore in the year-ago quarter. Basic EPS for Q4 FY26 was ₹3.84 (Q4 FY25: ₹2.37). For the full year, basic EPS was ₹15.08 (FY25: ₹11.72). Diluted EPS for FY26 was ₹15.06 (FY25: ₹11.71).

Standalone FY26 numbers also show growth

On a standalone basis, revenue from operations grew to ₹452.77 crore in FY26 from ₹351.41 crore in FY25. Standalone net profit rose to ₹131.81 crore from ₹102.42 crore in the previous year. The company presented these as audited annual results approved by the board.

Balance sheet disclosures: assets and equity

Advanced Enzyme reported consolidated total assets of ₹1,838.76 crore as of March 31, 2026, up from ₹1,621.35 crore as of March 31, 2025. Consolidated total equity increased to ₹1,683.12 crore from ₹1,468.67 crore over the same period. These figures were disclosed alongside the audited annual results.

Final dividend proposed; interim dividend deferred

The board recommended a final dividend of ₹1.35 per equity share for FY26, subject to shareholder approval at the ensuing 37th Annual General Meeting. The company stated this equals 67.5% on the face value of ₹2 per share. At the same meeting, the board decided to defer the declaration of an interim dividend. It cited the need to preserve capital flexibility while evaluating potential strategic avenues and corporate actions aimed at long-term shareholder value.

Director appointments and auditor reappointment

The board approved the re-appointment of Mr. Mukund Madhusudan Kabra (DIN: 00148294) as Whole Time Director for five years from April 01, 2027 to March 31, 2032, subject to shareholder approval at the 37th AGM. It also approved the appointment of Mr. Pradip Bhailal Shah (DIN: 01225582) as an Additional Director (Independent) effective June 12, 2026, for five years up to June 11, 2031, subject to member approval. In addition, the board approved the reappointment of M S K A & Associates LLP, Chartered Accountants (FRN: 105047W/W101187), as statutory auditors for a second term of five consecutive years, from the conclusion of the 37th AGM till the conclusion of the 42nd AGM. The statutory auditors issued an unmodified audit opinion on the standalone and consolidated FY26 results.

ESOP allotment increases paid-up share capital

The board approved the allotment of 49,350 equity shares of face value ₹2 each under the Advanced Enzyme Technologies Limited Employees Stock Options Scheme 2022. Following this allotment, paid-up share capital increased from ₹22.38536 crore (11,19,26,800 shares) to ₹22.39523 crore (11,19,76,150 shares). The company disclosed these post-allotment figures as part of its board outcome.

Investor conference call: date, time, and dial-in

Advanced Enzyme announced a conference call for analysts and investors to discuss financial results for the quarter and year ended March 31, 2026. The company said the disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and communicated to exchanges on May 05, 2026 by Company Secretary and Head Legal, Sanjay Basantani. The call is scheduled for Tuesday, May 12, 2026 at 09:00 hours IST. Primary dial-in numbers shared were +91 86 3416 8438 and +91 86 4536 6489, with an international participant PIN of 4773312#. The company advised participants to dial in 5 to 10 minutes early.

Key numbers at a glance

Market reference points disclosed in the update

The data set included a BSE end-of-day snapshot showing a price of ₹298.45 at 15:29 on 06-03-2026, with a change of ₹4.10 (1.39%) and volume of 4,681 shares. It also listed a dividend yield figure of 1.46, as presented in the same compilation of disclosures. Separately, the company reiterated that the recommended final dividend requires shareholder approval at the 37th AGM.

Conclusion

Advanced Enzyme Technologies closed FY26 with higher consolidated and standalone revenue and profit, and its board proposed a ₹1.35 per share final dividend while deferring an interim dividend for capital flexibility. Alongside the results, the board approved director and auditor-related items and completed an ESOP share allotment that increased paid-up capital. The next near-term event on the calendar is the analyst and investor conference call scheduled for May 12, 2026 at 09:00 IST.